Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 15/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 10/20 | 0.46 |
| ▸ | PPARD | Q03181 | 10/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435248 | 1.00 | FFAR1 (0.53) | FFAR1MIFPPARGPPARDPPARA | |
| SCHEMBL9275740 | 1.00 | FFAR1 (0.53) | FFAR1MIFPPARGPPARDPPARA | |
| SCHEMBL28580843 | 0.89 | MIF (0.49) | FFAR1MIFPPARGPPARD | |
| SCHEMBL15687672 | 0.86 | FFAR1 (0.45) | FFAR1MIF | |
| SCHEMBL9979486 | 0.86 | FFAR1 (0.47) | FFAR1MIFPPARGPPARDPPARA | |
| SCHEMBL18512247 | 0.86 | FFAR1 (0.55) | FFAR1PPARGPPARDPPARA | |
| SCHEMBL15791414 | 0.86 | PPARG (0.46) | FFAR1PPARGPPARDPPARA | |
| SCHEMBL15292395 | 0.86 | FFAR1 (0.55) | FFAR1PPARGPPARDPPARA | |
| SCHEMBL16609828 | 0.86 | FFAR1 (0.55) | FFAR1PPARGPPARDPPARA | |
| SCHEMBL14378498 | 0.85 | FFAR1 (0.42) | FFAR1MIFPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2914580-B1 | THIOARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEMICAL LTD (KR) | 2019-02-20 | — | — | EP | disclosed |
| EP-3105213-B1 | DIHYDROBENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF DIABETES AND OBESITY | TAKEDA PHARMACEUTICALS CO (JP) | 2019-01-09 | — | — | EP | disclosed |
| US-9969705-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-15 | — | — | US | disclosed |
| US-9783522-B2 | 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-9783522-B2 | 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-9597310-B2 | Indanyloxydihydrobenzofuranylacetic acids | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-21 | — | — | US | disclosed |
| US-9597310-B2 | Indanyloxydihydrobenzofuranylacetic acids | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-21 | — | — | US | disclosed |
| US-9597310-B2 | Indanyloxydihydrobenzofuranylacetic acids | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-21 | — | — | US | disclosed |
| EP-2953681-B1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INT (DE) | 2017-03-15 | — | — | EP | disclosed |
| EP-2953681-B1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INT (DE) | 2017-03-15 | — | — | EP | disclosed |
| WO-2014082918-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-05 | — | — | WO | disclosed |
| WO-2014082918-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-05 | — | — | WO | disclosed |
| US-20140148462-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-29 | — | — | US | disclosed |
| US-20140148462-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-29 | — | — | US | disclosed |
| US-20140148462-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-29 | — | — | US | disclosed |
| WO-2014069963-A1 | THIOARYL DERIVATIVES AS GPR120 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2014-05-08 | — | — | WO | disclosed |
| EP-2646425-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | Boehringer Ingelheim International GmbH (DE) | 2013-10-09 | — | — | EP | disclosed |
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| WO-2012081570-A1 | LACTAM COMPOUND OR A SALT THEREOF, AND PPAR ACTIVATOR | あすか製薬株式会社 (JP) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012072691-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148462-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | GPR119, GPBAR1, GPR55 | FFAR1 8/4885MIF 1113/4885PPARG 38/4885 |
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | GPR119, INSR, GPR52 | FFAR1 7/4885MIF 939/4885PPARG 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.